Epidemiology_Unit_2_Assignment.docx Unit 2 Assignment Cervical Cancer Screening Purdue Global University MN 503 The US Preventive Task Force provides guidelines for diseases such as cervical cancer. This task forc
...
Epidemiology_Unit_2_Assignment.docx Unit 2 Assignment Cervical Cancer Screening Purdue Global University MN 503 The US Preventive Task Force provides guidelines for diseases such as cervical cancer. This task force discusses the preventive measures, risk factors, statistics, morbidity, prevalence of each condition, risk assessments, testing, and the population most affected by each disease. In this paper, we will be discussing Cervical Cancer, epidemiology, testing and screening, prevention, population it affects, treatment, and prevention. Cervical Cancer Epidemiology “The cervix is lined by stratified squamous epithelium that covers the exocervix and mucusâ€secreting columnar epithelium characteristic of the endocervical canal. The transition between these 2 populations of cells is called the squamocolumnar junction, and it is this area that is believed to be at greatest risk of viral neoplastic transformation. Tumors arising in the ectocervix are most often squamous cell carcinomas, which account for approximately 75% of invasive cervical carcinoma cases. In contrast, tumors arising from the endocervix are more likely to be adenocarcinomas. Adenosquamous, small cell or neuroendocrine, serous papillary, and clear cell carcinomas of the cervix are less common histological subtypes†(Small et al., 2017). Most cases of cervical cancer are a result from the Human Papillomavirus (HPV), and the majority of these cases will clear on their own when they become infected. However, in some cases they b. . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . .. .. . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
[Show More]
